
|Videos|February 23, 2023
Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific
Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5





























